HOPE-1

Details

Therapeutic category
Mucociliary Clearance
Trial status
Completed Participating Centres
Phase
Phase II

Full title

A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness)

Evaluation of potential mucus clearing treatment for all patients with CF regardless of mutation
Trial Reference Number
99066
Trial type
Medication
Intervention
ENaC inhibitor (mucociliary clearance)
Recruitment target
80
Last edited date
02/10/2017
CF sponsor
Spyryx Biosciences, Inc.
CF sponsor type
Commercial

Who can take part?

Age
18+
Top inclusion criteria
  • Age 18 years or older
  • Stable CF Lung Disease
Top exclusion criteria
  • Significant unstable co-morbidities within 28 days of screening.
  • Has received an investigational drug within 28 days of screening

Your donation will make a difference:

Select amount